AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32947459 — intervention group
Group type: COMPARATOR
Intervention: No moisturizer (applied to the opposite forearm)
Number of subjects: 20
Study 32947459 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizers (general intervention)
Number of subjects: 20
Study 36086755 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and electronic moxibustion (EM) cotreatment, 3 times a week for 6 weeks, alongside previously prescribed alpha blocker.
Number of subjects: 28
Study 36086755 — intervention group
Group type: COMPARATOR
Intervention: Control group continued to use the previously prescribed alpha blocker alone for 6 weeks.
Number of subjects: 28
Study 32571960 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+LUS (Physical Examination + Lung Ultrasound)
Number of subjects: 244
Study 32571960 — intervention group
Group type: COMPARATOR
Intervention: PE only (Physical Examination only)
Number of subjects: 244
Study 32571960 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+LUS
Number of subjects: 244
Study 32571960 — intervention group
Group type: COMPARATOR
Intervention: PE only
Number of subjects: 244
Study 36255063 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (answered anchoring tasks immediately after being awakened at nighttime)
Number of subjects: 104
Study 36255063 — intervention group
Group type: COMPARATOR
Intervention: Control group (answered anchoring tasks at daytime)
Number of subjects: 104
Study 32690388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy for non-true bifurcation lesions
Number of subjects: 206
Study 32690388 — intervention group
Group type: COMPARATOR
Intervention: Aggressive strategy for non-true bifurcation lesions
Number of subjects: 206
Study 32690388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative strategy for true bifurcation lesions
Number of subjects: 206
Study 32690388 — intervention group
Group type: COMPARATOR
Intervention: Aggressive strategy for true bifurcation lesions
Number of subjects: 206
Study 33824084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Positioning (PP)
Number of subjects: 114
Study 33824084 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 114
Study 33579855 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at a gym or sports club
Number of subjects: 455258
Study 33579855 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at religious group
Number of subjects: 455258
Study 32584510 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 225
Study 32917251 — intervention group
Group type: EXPERIMENTAL
Intervention: Vessel-sparing anastomotic repair (vsAR)
Number of subjects: 100
Study 32917251 — intervention group
Group type: COMPARATOR
Intervention: Transecting anastomotic repair (tAR)
Number of subjects: 100
Study 33544052 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored temporal message frames that align with individuals' CFC
Number of subjects: 450
Study 33544052 — intervention group
Group type: EXPERIMENTAL
Intervention: Operationalization of risk perception (susceptibility only, severity only, or combination of the two)
Number of subjects: 450
Study 35446230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for generalized anxiety disorder (GAD)
Number of subjects: 80
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bleaching+antioxidant with PIPS-activated irrigation (CB-PIPSI)
Number of subjects: 105
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bleaching+antioxidant with PIPS-activated irrigation (MB-PIPSI)
Number of subjects: 105
Study 33577388 — intervention group
Group type: COMPARATOR
Intervention: Control (no bleaching/antioxidant)
Number of subjects: 105
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bleaching only (CB)
Number of subjects: 105
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bleaching only (MB)
Number of subjects: 105
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bleaching+antioxidant with needle irrigation (CB-NI)
Number of subjects: 105
Study 33577388 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified bleaching+antioxidant with needle irrigation (MB-NI)
Number of subjects: 105
Study 32998206 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium creatine chelate (MgCr‐C) supplementation, 5500 mg (0.07 g/kg/d) in 4 capsules per day
Number of subjects: 20
Study 32998206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch in identical 4 capsules)
Number of subjects: 20
Study 32998206 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium creatine chelate (MgCr‐C) supplementation
Number of subjects: 20
Study 35747502 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal growth factor receptor-targeted therapy
Number of subjects: 858
Study 35747502 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 858
Study 32901962 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment with tissue-level restoration (TL group)
Number of subjects: 65
Study 32901962 — intervention group
Group type: EXPERIMENTAL
Intervention: Root canal treatment with normal occlusal contacts (OC group)
Number of subjects: 65
Study 32901962 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients with root canal treatments)
Number of subjects: 65
Study 34018096 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥ 5%)
Number of subjects: 94
Study 34018096 — intervention group
Group type: COMPARATOR
Intervention: < 5% weight loss
Number of subjects: 94
Study 32013946 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention for community health workers (CHWs)
Number of subjects: 0
Study 32013946 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 35421771 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant low-temperature cold spray (programme A; n = 47)
Number of subjects: 145
Study 35421771 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-to-normal temperature spray (programme B; n = 49)
Number of subjects: 145
Study 35421771 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group; n = 49)
Number of subjects: 145
Study 34061938 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 simulation
Number of subjects: 69
Study 34061938 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 simulations
Number of subjects: 69
Study 34061938 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 simulations
Number of subjects: 69
Study 34061938 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 69
Study 35076746 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider‐assisted turbinoplasty (MAT)
Number of subjects: 70
Study 35076746 — intervention group
Group type: COMPARATOR
Intervention: Quantum molecular resonance (QMR)
Number of subjects: 70
Study 32890647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion imaging with a mobile flat plane sensor (Cios Alpha, Siemens) and angionavigation station (EndoNaut, Therenva)
Number of subjects: 41
Study 35463348 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose chemoradiotherapy (rdCRT) (56 Gy) with weekly carboplatin
Number of subjects: 20
Study 35463348 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (sdCRT) (70 Gy)
Number of subjects: 20
Study 32381186 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 2488
Study 32381186 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2488
Study 32381186 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES) in small vessels
Number of subjects: 2488
Study 32381186 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES) in small vessels
Number of subjects: 2488
Study 35307727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enteral nutrition combined with microbial preparations
Number of subjects: 160
Study 35307727 — intervention group
Group type: COMPARATOR
Intervention: Traditional intestinal preparation (control)
Number of subjects: 160
Study 35535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 37
Study 35535772 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for Insomnia (ACT‐I)
Number of subjects: 37
Study 33951124 — intervention group
Group type: EXPERIMENTAL
Intervention: polyethylenglycol 4L (PEG)
Number of subjects: 431
Study 33951124 — intervention group
Group type: EXPERIMENTAL
Intervention: oral sulfate solution (OSS)
Number of subjects: 431
Study 33951124 — intervention group
Group type: EXPERIMENTAL
Intervention: 2L polyethylenglycol + ascorbate (2L‐PEG/Asc)
Number of subjects: 431
Study 33951124 — intervention group
Group type: EXPERIMENTAL
Intervention: magnesium citrate + sodium picosulfate (MCSP)
Number of subjects: 431
Study 32184607 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 1-Month (PP1M)
Number of subjects: 1016
Study 32184607 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 3-Month (PP3M)
Number of subjects: 1016
Study 36166682 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propafenone
Number of subjects: 193
Study 36166682 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propafenone
Number of subjects: 193
Study 36166682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 34191016 — intervention group
Group type: EXPERIMENTAL
Intervention: Mel4‐coated antimicrobial contact lenses (MACLs)
Number of subjects: 176
Study 34191016 — intervention group
Group type: COMPARATOR
Intervention: Uncoated control contact lenses
Number of subjects: 176
Study 32306008 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition support in addition to chemotherapy
Number of subjects: 118
Study 32306008 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (Control)
Number of subjects: 118
Study 36283797 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory distress symptom intervention (RDSI)
Number of subjects: 263
Study 36283797 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 263
Study 36355652 — intervention group
Group type: EXPERIMENTAL
Intervention: Training (workshops and ongoing consultations)
Number of subjects: 117
Study 36355652 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 117
Study 34635178 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced ATTC strategy (including Pay-for-Performance and Implementation & Sustainment Facilitation)
Number of subjects: 30
Study 34635178 — intervention group
Group type: COMPARATOR
Intervention: Addiction Technology Transfer Center (ATTC) Network implementation strategy (control condition)
Number of subjects: 30
Study 35606883 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140mg) administration once within 72 h before CABG
Number of subjects: 100
Study 35606883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no administration)
Number of subjects: 100
Study 35606883 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140mg) administration
Number of subjects: 100
Study 33533487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 401
Study 33533487 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 401
Study 33533487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 assessment
Number of subjects: 401
Study 33533487 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MRI and Ki-67
Number of subjects: 401
Study 32291649 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous condition (different synesthetic colors for familiar graphemes)
Number of subjects: 0
Study 32291649 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous condition (same synesthetic color for familiar graphemes)
Number of subjects: 0
Study 35339669 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind peppermint oil
Number of subjects: 173
Study 35339669 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo
Number of subjects: 173
Study 35339669 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 173
Study 34479601 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐?1a (11?g or 3MIU) injected subcutaneously at day 1, 3, 7, and 10 in addition to standard of care
Number of subjects: 60
Study 34479601 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐?1a
Number of subjects: 60
Study 34479601 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study 32141389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as two times four cycles)
Number of subjects: 420
Study 32141389 — intervention group
Group type: COMPARATOR
Intervention: Continuous second-line chemotherapy (capecitabine or non-pegylated liposomal doxorubicin, given as eight consecutive cycles)
Number of subjects: 420
Study 32141389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent second-line chemotherapy
Number of subjects: 420
Study 32141389 — intervention group
Group type: COMPARATOR
Intervention: Continuous second-line chemotherapy
Number of subjects: 420
Study 36460046 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-based RT session with 10% velocity loss (VL10)
Number of subjects: 15
Study 36460046 — intervention group
Group type: COMPARATOR
Intervention: Traditional 1-repetition maximum-based RT session to failure (TRF)
Number of subjects: 15
Study 33478112 — intervention group
Group type: EXPERIMENTAL
Intervention: C+ (enzyme-containing toothpaste with glucose oxidase and D-glucose with Citrox)
Number of subjects: 20
Study 33478112 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS (sodium lauryl sulfate-containing toothpaste)
Number of subjects: 20
Study 33478112 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference (toothpaste without SLS)
Number of subjects: 20
Study 33478112 — intervention group
Group type: EXPERIMENTAL
Intervention: C− (enzyme-containing toothpaste with glucose oxidase and D-glucose without Citrox)
Number of subjects: 20
Study 33478112 — intervention group
Group type: COMPARATOR
Intervention: Water (control group)
Number of subjects: 20
Study 33171964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (0.425 g, 14% of ADI)
Number of subjects: 17
Study 33171964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralose (0.136 g, 20% of ADI)
Number of subjects: 17
Study 33171964 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame and Sucralose
Number of subjects: 17
Study 35690655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical face mask (SM)
Number of subjects: 23
Study 35690655 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtering face piece (FFP2)
Number of subjects: 23
Study 35690655 — intervention group
Group type: COMPARATOR
Intervention: No mask (NM)
Number of subjects: 23
Study 34563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial hydroxyurea treatment for children with SCA and abnormal transcranial Doppler (TCD) velocities
Number of subjects: 679
Study 34563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacity-building component of the trials
Number of subjects: 679
Study 34563875 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing TCD-based screening and funding for hydroxyurea
Number of subjects: 679
Study 35887829 — intervention group
Group type: EXPERIMENTAL
Intervention: Optilyte® infusion
Number of subjects: 25
Study 35887829 — intervention group
Group type: COMPARATOR
Intervention: Geloplasma® infusion
Number of subjects: 25
Study 32356211 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with tricalcium phosphate (TCP)
Number of subjects: 92
Study 32356211 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with xylitol‐coated calcium and phosphate (CXP)
Number of subjects: 92
Study 32356211 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride (SF) control group
Number of subjects: 92
Study 32356211 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride with casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP)
Number of subjects: 92
Study 35726497 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttherapeutic CBT skills usage frequency
Number of subjects: 241
Study 35726497 — intervention group
Group type: COMPARATOR
Intervention: Supported iCBT
Number of subjects: 241
Study 32890855 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on dorsal pathway
Number of subjects: 16
Study 32890855 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS on ventral pathway
Number of subjects: 16
Study 32890855 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 34344355 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical activity intervention
Number of subjects: 9
Study 35724843 — intervention group
Group type: EXPERIMENTAL
Intervention: Báa nnilah intervention group
Number of subjects: 0
Study 35724843 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 0
Study 32481239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor and gait training for eight weeks (3 days/week) along with diabetes and foot care education
Number of subjects: 38
Study 32481239 — intervention group
Group type: COMPARATOR
Intervention: Diabetes and foot care education only
Number of subjects: 38
Study 36096912 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital complete dentures (CDs) fabricated from intraoral scan data
Number of subjects: 8
Study 36096912 — intervention group
Group type: COMPARATOR
Intervention: Conventional complete dentures (CDs) fabricated by conventional workflow
Number of subjects: 8
Study 33065163 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 143
Study 33065163 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 143
Study 35211840 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine
Number of subjects: 44
Study 35211840 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 44
Study 36259475 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/day, oral)
Number of subjects: 52
Study 36259475 — intervention group
Group type: EXPERIMENTAL
Intervention: ET (Cycle ergometer, moderate intensity, 40-60% VO2 peak, three sessions/week for six weeks)
Number of subjects: 52
Study 36259475 — intervention group
Group type: EXPERIMENTAL
Intervention: MitoQ+ET
Number of subjects: 52
Study 36259475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35618267 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (NR)
Number of subjects: 11499
Study 33440972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalation without propofol infusion (group Sev)
Number of subjects: 100
Study 33440972 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion (group Pro)
Number of subjects: 100
Study 33440972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 32532321 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 0
Study 32532321 — intervention group
Group type: COMPARATOR
Intervention: Standard care (spectacles or contact lenses)
Number of subjects: 0
Study 33663735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 3660
Study 35157226 — intervention group
Group type: EXPERIMENTAL
Intervention: NORTH STAR prevention system
Number of subjects: 24
Study 35157226 — intervention group
Group type: COMPARATOR
Intervention: Assessment-and-feedback-only condition
Number of subjects: 24
Study 34776184 — intervention group
Group type: EXPERIMENTAL
Intervention: Manorah training (45 min/day, 3 days/week for 4 weeks)
Number of subjects: 34
Study 34776184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 32144059 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Anesthesia (TEA)
Number of subjects: 0
Study 32144059 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Injection Paravertebral Block (PVB)
Number of subjects: 0
Study 32144059 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral Catheter
Number of subjects: 0
Study 35725863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level tidal volume (HLVT)
Number of subjects: 26
Study 35725863 — intervention group
Group type: COMPARATOR
Intervention: High-level pressure support (HLPS)
Number of subjects: 26
Study 35655257 — intervention group
Group type: EXPERIMENTAL
Intervention: MASK-ED™ simulation (used in 5 out of 32 tutorials, 16%)
Number of subjects: 144
Study 35655257 — intervention group
Group type: COMPARATOR
Intervention: Role-play with peers (control group)
Number of subjects: 144
Study 35655257 — intervention group
Group type: EXPERIMENTAL
Intervention: MASK-ED™ simulation (experimental group)
Number of subjects: 144
Study 32710391 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P13 (biosimilar infliximab) given as a single infusion of 5 to 10 mg/kg
Number of subjects: 21
Study 35907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (VRT) - active content
Number of subjects: 35
Study 35907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (VRT) - passive content
Number of subjects: 35
Study 35907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall VRT experience
Number of subjects: 35
Study 35907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 35
Study 33788933 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 4103
Study 33788933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 4103
Study 33788933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 4103
Study 33788933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4103
Study 32860031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen 40 mg Q4W
Number of subjects: 105
Study 32860031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen 80 mg Q4W
Number of subjects: 105